Moderna, Inc. MRNA

Moderna’s latest 10-Q for the quarter ending 31 March 2026 shows a company haemorrhaging cash at a startling rate: net loss of $1.34 billion, operating loss of $1.39 billion, and operating cash burn of $630 million, all while revenue climbed 260% year-on-year to $389 million. The sales surge was driven by $266 million of additional net product sales-almost entirely from COVID vaccine deliveries to international governments under long-term supply contracts. Deferred revenue at 31 March stood at $95 million, of which $37 million is expected within a year, leaving the rest as future promises on the balance sheet. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm)

Moderna remains a company built on a single product class-vaccines-despite ambitions to expand into flu, RSV, CMV, Zika, HIV, and oncology via mRNA technology. The product pipeline page is a glossy showcase of aspirational candidates, but the regulatory reality is thin: no new approvals have been added to the SEC filings in the last six months, and the filing index shows only routine updates. The company’s ability to pivot from pandemic hero to diversified biotech relies on turning lab benchmarks into commercial products, something the current filings have yet to evidence. (source: Modernatx product pipeline page, https://www.modernatx.com/research/product-pipeline)

Cash and equivalents at quarter end were $1.91 billion, down from $2.54 billion at year end 2025, while liabilities rose to $4.08 billion and stockholders’ equity fell to $7.41 billion. Research and development spend was $649 million in the quarter, capital expenditure $62 million, and inventory net $146 million, indicating Moderna is still burning through capital to keep its manufacturing and supply chains warm while waiting for the next approval cycle. Earnings per share came in at minus $3.40 on a diluted share count of 395 million, a figure that would make even the most optimistic dividend dreamer return to the evidence. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm)

If you’re looking for a chart, the SEC filings don’t plot price action-only regulatory filings, insider trades, and deferred revenue timelines. For a visual of Moderna’s share price behaviour, consult a charting platform; the company’s own sources stop at the balance sheet. What the filings do show is a company caught between two worlds: the legacy COVID franchise that still drives revenue, and the future mRNA pipeline that has yet to prove its mettle. Until that pipeline delivers real products, the balance sheet is the only story in town. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1682852)

The insider trading signal is mixed. Over June, multiple Form 4 and Form 144 filings show executives adjusting positions, but the SEC documents do not disclose the reasons, leaving the market to guess between option exercises, planned sales, or portfolio rebalancing. The absence of clear narrative around these filings adds opacity to an already opaque story: Moderna’s core franchise is shrinking, its diversification is aspirational, and its cash burn is accelerating. Until the next product approval or a clear path to profitability emerges, the focus will remain on the burn rate and the deferred revenue clock. (source: SEC EDGAR Form 4 and Form 144 filings June 2026, https://www.sec.gov/Archives/edgar/data/1682852/)